The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tesetaxel, an advanced-generation oral taxane, as first-line treatment in women with metastatic breast cancer.
L. S. Schwartzberg
No relevant relationships to disclose
M. Beeram
Research Funding - Genta
A. Patnaik
Research Funding - Genta
A. W. Tolcher
Consultant or Advisory Role - Genta (U)
Research Funding - Genta
L. Itri
Employment or Leadership Position - Genta (B)
Stock Ownership - Genta (B)
A. L. Olson
No relevant relationships to disclose
A. D. Seidman
No relevant relationships to disclose